ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1442

Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus

Renata Baronaite Hansen1, Julia Simard2, Mikkel Faurschou1 and Søren Jacobsen3, 1Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 3Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Meeting: ACR Convergence 2023

Keywords: Comorbidity, Myocardial Infarction, Peripheral Vascular Disease, Stroke, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence of vascular events, – by age and sex, – in a large inception cohort of patients with SLE compared with matched general population controls.

Methods: We assembled a cohort of adult patients registered with a first-time diagnosis of SLE (ICD codes) from January 1996 to July 2018 in the Danish National Patient Register (DNPR). SLE patients were age, – and sex-matched to population controls randomly selected from the Danish Civil Registration System. We used ICD codes from the DNPR to determine the presence of cardiovascular disease (Myocardial Infarction (MI)), cerebrovascular disease (CVD), and peripheral vascular disease (PVD) during outpatient and inpatient care. Individuals with prevalent MI, CVD, and PVD at baseline (SLE diagnosis) were excluded from the analyses of incident events. We estimated incidence rates (IRs), incidence rate ratios (IRRs), and incidence rate differences (IRDs) per 1,000 person-years of MI, CVD, and PVD by sex and age (< 50 years vs ≥ 50 years at baseline) during up to 10 years of follow-up. Analyses were done separately for each disease category, e.g., individuals with incident MI were retained for analyses of CVD and PVD. IRRs and IRDs were adjusted for age and sex using Poisson regression and presented with 95% CIs.

Results: We identified 3,178 patients with incident SLE and 60,090 age- and sex-matched general population comparators. 84% of SLE patients and non-SLE controls were female; the mean age at baseline was 47 years. At baseline, the prevalence of MI (2.9% vs 1.40%), CVD (7.0% vs 2.7%), and PVD (5.5% vs 1.4%) was higher in SLE patients compared with the general population controls.

During follow-up, patients with SLE had substantially increased IRs of the above vascular events, with IRRs ranging from 1.7 to 7.6 across sex and age groups (Table 1). Although the absolute rates (IRs) were higher in SLE patients vs controls in the older age group, the IRRs were consistently higher for those aged < 50 at baseline, both females and males. In this age group, female SLE patients had a 5-fold increased risk of CVD and PVD and a 3-fold increased risk of MI. Male SLE patients had an 8-fold increased risk of PVD and a 6-fold increased risk of CVD and MI.

The IRDs ranged from 0.7 (MI in females aged < 50) and 11.4 (PVD in males aged ≥ 50) (Table 1). Interestingly, IRDs were higher in males vs females in both age groups for MI and PVD, and in the younger age group for CVD.

Conclusion: In this nationwide study utilizing prospectively collected registry data, incident patients with SLE were more likely to develop vascular disease than general population controls during up to 10 years of follow-up after SLE diagnosis. This was seen for women and men aged less or more than 50 years at the time of diagnosis but with the highest IRRs of MI, CVD, and PVD in the younger group of SLE patients. Male subjects had a higher incidence of vascular disease, reflected in male SLE patients having the highest IRDs for MI and PVD. Our findings highlight the need for a thorough assessment of vascular comorbidities in SLE patients, at the time of SLE diagnosis and during follow-up, irrespective of sex and age.

Supporting image 1

Table 1. Measures of occurrence and association (per 1,000 person-years, with 95% CI) of incident vascular events in patients with incident SLE (n=3,178) compared with matched population controls (n=60,090) during up to 10 years of follow-up after SLE diagnosis, stratified by sex and age group


Disclosures: R. Baronaite Hansen: None; J. Simard: None; M. Faurschou: None; S. Jacobsen: Bristol-Myers Squibb(BMS), 5.

To cite this abstract in AMA style:

Baronaite Hansen R, Simard J, Faurschou M, Jacobsen S. Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/incident-vascular-events-in-danish-nationwide-cohort-of-patients-with-newly-diagnosed-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incident-vascular-events-in-danish-nationwide-cohort-of-patients-with-newly-diagnosed-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology